Roy Baynes, Merck Research Laboratories CMO (file photo)
In tight next-gen pneumococcal vaccine race with Pfizer, Merck reads out topline pediatric data
The FDA is set to decide on Pfizer’s 20-valent pneumococcal conjugate vaccine for adults in June — a month before Merck’s PDUFA date for its 15 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
